Ridgeback Capital Investments L.P. — 13F Holdings

2026 Q2  ·  2 Positions

2026 Q2 Portfolio Activity

In 2026 Q2, Ridgeback Capital Investments L.P. maintained a portfolio of 2 distinct positions. The most significant new addition was Replimune Group Inc., now representing 100.00% of the total fund value. Conversely, Ridgeback Capital Investments L.P. completely exited their position in Pyxis Oncology Inc.
Position History hover any row below to update
Loading…
PCA Score Concentration Risk
Risk ENB
Total Positions
2
Quarter
2026 Q2
Top Holding
REPL (100.0%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-2 of 2

Ridgeback Capital Investments L.P. Full Holdings List — 2026 Q2

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
REPL
Replimune Group...
Healthcare 100.00% #1
Prev: #—
9.5
7,310,656
NEW
7,310,656 $80,928,962
$11.07 +16.7%
$11.07 +16.7%
2026 Q2 13F Filing 2026-06-30 2026-08-14
PYXS
Pyxis Oncology ...
Healthcare 0.00% 100.00%
Sold All 😨
(Was: #1)
0.0
-359,231 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2026-06-30 2026-08-14
Showing 1-2 of 2 holdings

Unlock Full Ridgeback Capital Investments L.P. Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →